Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What a pain OTCX is. I sometimes like to mess with their algorithms just for fun...lol
Maybe some good news coming. Nice bounce and volume.
Transphorm Co-Founder, President and COO Primit Parikh Scheduled to Appear on Fox Business Network’s The Claman Countdown Today Around 3:30 pm EDT
GOLETA, Calif.--(BUSINESS WIRE)-- Transphorm, Inc. (OTCQB: TGAN)—a pioneer in and global supplier of high reliability, high performance gallium nitride (GaN) power conversion products, announced today its co-founder & COO, Primit Parikh, Ph.D., is scheduled to be a guest on the Fox Business Network’s show, The Claman Countdown today around 3:30 pm EDT.
https://www.otcmarkets.com/stock/TGAN/news/story?e&id=1845918
Migom Global Corp. Launches its Private Closed-Loop Payment System at Migom Bank
Press Release 03/22/2021
Migom Global Corp. (OTC: MGOM), via Migom Bank®, brings MigomPay its innovative Closed-Loop QR Code Payment System to market, further expanding the service footprint and allowing the Company to access a key growth segment.
Closed-loop payment systems remain a key growth area in financial service provision. According to US market research company eMarketer, mobile payments increased by 41% in the US alone in 2018-19. Against this backdrop, corporate entities may adopt a competitive approach to retain and entice their customer base. The Companys wholly-owned subsidiary, Migom Bank can enable point of sale and online merchants to operate the closed-loop model based on secure QR Code-based payments.
Merchants and customers should be enticed by the incentives that our QR Code closed loop payment systems can offer. There are no chargebacks, long held reserve funds, equipment rentals, delays in funds settlement and the very high fees typically associated with usage of traditional payment cards online and in brick and mortar shops, stated Georgi Parrik, the CEO of the Company. Furthermore, merchants may be awarded with additional residual income when their customers, who started to use our QR Payments, engage in other banking services, which we may offer. That way a heavy expense item, when merchants give away up to a quarter of their profit for payment processing, may become an additional revenue center for the merchants for the life of those customers accounts at Migom Bank.
The Company has invested in the development of its own software supporting the QR closed loop payment system and expects to gain significant traction with merchants and customers globally due to our customer first design and rigorous, yet agile approach to compliance in unbanked markets. We are looking at the opportunities to implement this system tentatively named MigomPay in test markets in the Caribbean and the Middle East.
https://www.otcmarkets.com/stock/MGOM/news/Migom-Global-Corp-Launches-its-Private-Closed-Loop-Payment-System-at-Migom-Bank?id=294568
No, was wondering the same.
Yep, the old DTC chill on YTFD, just called TDA.
Looks like this is new website:
https://sumnets.com/
Thanks. Could run nice with this low float.
ECRD getting some early morning action...hmmm
ECRD getting some early morning action...hmmm
I feel like.....
FORM 8-K out
Item 8.01. Other Events
On March 14, 2021, Gushen, Inc. (“GSHN”) entered into a non-binding letter of intent to consummate a potential share exchange with Dyckmanst Limited, a company organized under the laws of the British Virgin Islands (the “Acquiree Company”) and its shareholders. The Acquiree Company, through its variable interest entity in China, Beijing Zhuoxun Century Culture Communication Co., Ltd. (“Beijing Zhuoxun”), is engaged in platform business of onsite and online family education. The Acquiree Company’s equity valuation is estimated to be no more than US$ 100 million, subject to completion of due diligence.
https://www.otcmarkets.com/filing/html?id=14799660&guid=yEWaUnnQ9HHTN3h
$8 hits.
CINV saw that. Nice
Agreed ELVG.
ELVG 35k volume, 22k bidder.
ELVG has a pulse. 35k volume
Ok, didn't catch that, sounds good.
CINV nice!
FORM 8-K
Item 1.01. Entry into a Material Definitive Agreement
On January 3, 2021, Khashing Yachts Industry (Guangdong) Limited Company, our wholly owned subsidiary in Guangzhou, China, entered into a Joint Venture and Cooperation Agreement with Shenzhen Ocean Way Yachts Service Co., Ltd (“Ocean Way”). Under this agreement, we will acquire 60% of the total issued and outstanding shares of Ocean Way and will utilize Ocean Way’s established yacht database, yacht resources and its media resources to expedite our growth. We expect to significantly increase the company's influence in the Chinese yacht industry by this transaction.
Ocean Way was formed in 2013 and is a comprehensive Chinese yacht service provider. It owns multiple platforms including magazine, new media and online yacht mall. It has a proprietary yacht database and has been providing customized and accurate market study reports for yacht event organizers, sellers ad manufacturers since 2019. It has produced a number of publications including “2015 Ocean Way China Yacht Market Study” and “2017 Ocean Way China Yacht Market Study” which were the unique market reports for Chinese yacht market.
https://www.otcmarkets.com/filing/html?id=14791793&guid=1OxaUezd2BLks3h
Yeah, the Russell 2000 did nothing for XCUR IMO. Would love to see nice run here. The company speaks for itself, maybe not loud enough...lol
Agreed, tons of potential here. Not to mention the FY20 sales results of $16.6 mill.
That's right. Bring on the filings and news. Something is going on IMO.
Well let's go I'm ready!
Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have utilized Exicure’s licensed first generation gold-nanoparticle SNA technology in an investigator-initiated trial for the treatment of glioblastoma (GBM), a deadly form of brain cancer.
The results were published in an article in Science Translational Medicine. https://stm.sciencemag.org/content/13/584/eabb3945 DOI:10.1126/scitranslmed.abb3945
The researchers that led the study, Drs. Priya Kumthekar and Alexander Stegh, conducted a single-arm, open-label phase 0 first-in-human clinical trial (NCT03020017) to determine safety, pharmacokinetics, intratumoral accumulation and gene-suppressive activity of systemically administered SNAs comprised of siRNA specific for the GBM oncogene Bcl2L12. Patients with recurrent GBM were treated with intravenous administration of siBcl2L12-SNAs (NU-0129).
The paper reports first-in-human evidence that siRNA-based SNAs can be administered intravenously, cross the blood-brain-barrier in glioblastoma patients, accumulate in GBM tumor cells, and engage with their target gene.
“We congratulate Drs. Kumthekar and Stegh on these results,” said Dr. David Giljohann, the CEO of Exicure. He added, “We are excited about the impact to patients and its implications in treating other diseases, as Exicure continues to build and grow our pipeline in neurological disorders.”
Exicure anticipates filing an IND for its lead program in Friedreich’s ataxia by the end of 2021.
https://www.otcmarkets.com/stock/XCUR/news/story?e&id=1836387
Migom Global Corp. Celebrates 1st birthday of BTC Bank Account at Migom Bank®
Press Release | 03/10/2021
Migom Global Corp. (OTC: MGOM), announces its move to scale client onboarding at Migom Bank® after celebrating the anniversary of its world's first, fully functional BTC Bank Account.
There remains a substantial gap in regulated service provision within the
cryptocurrency market, particularly amongst exchanges and e-money service
providers. Our significant investment in technology and regulatory framework places us to benefit from a market with estimates of annual growth ranging from 45.4% to 75.4% to 2027 Stated Thomas Schtti, the president of Migom Global Corp.
He continues We can onboard customers into the cryptocurrency journey without the need for a fiat ramp, exchange and additional custodial wallet. With a single source of compliance, backed by bank-grade security and rigid, yet efficient regulatory framework, we are setting new standards in digital asset issuance, trading and custody. In simple terms, every client who qualifies for an account at Migom Bank® can immediately and safely operate in major fiat currencies as well as the three top cryptocurrencies inside one account. Customers can make these transactions on one screen with the operational backbone and custody provided by our partner financial institutions in Switzerland and the USA. We treat cryptocurrencies just the same as money and have simplified their usage to how its supposed to work globally, without sacrificing any compliance procedures or regulatory requirements.
Migom bank sees further upside to the adoption of blockchain-based assets as the US dollar strengthens, driving emerging markets into cryptocurrencies, which are less vulnerable to dollar denominated control than traditional commodities. To further its market penetration Migom Bank plans to add several mainstream cryptocurrencies as well as work on origination of new blockchain-based stable assets in due course.
https://www.otcmarkets.com/stock/MGOM/news/Migom-Global-Corp-Celebrates-1st-birthday-of-BTC-Bank-Account-at-Migom-Bank?id=293216
Thanks for the info. Will be watching for updates.
Same here, they (MMs) know who to cater to.
Hopefully we can get some at a reasonable price...lol
Daily List: Symbol/Name Change effective 3/11/21
New symbol: INSD
New name: Instadose Pharma Corp.
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Should have waited for the fire sale today.
Picked some up today.
That is quite a spread, $3-ish would be nice IMO.
AUGX new issue shares available. MM RILY $3/10
https://www.otcmarkets.com/stock/AUGX/security
https://www.augmedix.com/
Lol. I hear ya. Gonna need the paddles to get this back to life. Been way too long, I agree.
Transphorm’s GaN Products Meet Crypto Mining Power Supply Units Performance Requirements
High Reliability, High Performance, and Robust Packaging Underscore Company’s Value for Crypto Mining Application
GOLETA, Calif.--(BUSINESS WIRE)-- Transphorm, Inc. (OTCQB: TGAN)—a pioneer in and global supplier of high reliability, high performance gallium nitride (GaN) power conversion products, announced today that its device portfolio is optimally designed and proven to support the growing demand for high performing power supply units (PSUs) driving the mining of cryptocurrencies such as Bitcoin.
The Company’s GaN FETs are proven to reliably perform under harsh environments with high efficiency in various power applications, thereby minimizing wasted electricity. Transphorm is the only high voltage GaN supplier to date to publicly announce a customer’s products currently in production are known to be used for crypto mining purposes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005483/en/
https://www.otcmarkets.com/stock/TGAN/news/story?e&id=1829203
Few buys coming in early today.
Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod
March 03, 2021 07:00 AM Eastern Standard Time
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its clinical product candidate, cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma (MCC).
“We are excited to have been granted Orphan Drug Designation by the FDA for cavrotolimod for MCC,” said Dr. Douglas Feltner, Chief Medical Officer of Exicure. “This designation marks significant progress toward our goal of fulfilling the unmet medical need and finding a treatment for Merkel cell carcinoma patients.”
Exicure previously announced that the FDA granted two Fast Track designations for cavrotolimod (AST-008) for MCC and cutaneous squamous cell carcinoma (CSCC), both in the advanced/metastatic setting after progression on anti-PD-1/PD-L1 antibodies.
About Orphan Drug Designation
Orphan Drug Designation is a designation granted by the FDA which provides orphan status to drugs or biologics which are intended to treat rare diseases or disorders that affect fewer than 200,000 people in the United States. This designation provides the sponsor of the drug certain incentives, including tax credits for qualified clinical trials and fee waivers. Orphan Drug Designation confers eligibility for seven years of market exclusivity to an orphan drug post-approval, subject to a receipt by the FDA of marketing approval.
https://www.otcmarkets.com/stock/XCUR/news/story?e&id=1827806
Global WholeHealth Partners Corp (GWHP-OTC) to Announce an Antibody “Confident” Test Which Can Detect the S1 RDT Antigen Used in COVID 19 Vaccines
People are looking to be confident in the vaccine working. After all the news of vaccines not working as well as we had hoped, people want to know, did the vaccine I received work?
Global’s Antibody “Confident Test” can detect the S1 RDT Antigen in Vaccines. The test is sensitive enough to be able to detect the S1 RDT Antigen in Blood, Saliva, and Urine. Once a person gets the vaccine, the person can be tested to see if the vaccine took effect.
San Clemente, March 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest line of COVID 19 tests. Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses. The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein. Global understands the need to be ahead of the virus to conquer the virus.
“This is a wartime undertaking,” President Biden said. “Today, I’m signing executive action to use the Defense Production Act and all other available authorities to direct all federal agencies and private entities to accelerate the making of everything that’s needed to protect, test, vaccinate, and take care of our people.” https://philadelphia.cbslocal.com/2021/01/21/president-joe-biden-country-at-war-coronavirus/
Under Mr. Strongo’s direction, Global is following the President and his leadership and is making a war on COVID. To conquer COVID and win this war, Global must keep up the research and development of tests.
Read full article:
https://www.otcmarkets.com/stock/GWHP/news/story?e&id=1827757
Good question.
Global WholeHealth Partners Corp (GWHP-OTC) to Announce That the Antibody Test Kits Offered by Global Can Detect the S1 Protein Used in COVID 19 Vaccines
People want to know if the vaccine worked; Global’s test will help people know if the IgG antibody is forming after the vaccine.
Global's Antibody test can detect the new CoViD 19 SARS 2 strains and detect if the vaccine was able to produce the antibody IgG in the recipient of the vaccine.
San Clemente, March 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Charles Strongo, CEO of Global WholeHealth Partners Corp (OTC:GWHP), comments on https://www.cbsnews.com/news/covid-death-toll-united-states-expected-500k-february/ regarding the potential of 500,000 deaths by mid-February, as stated by the incoming director of the Centers for Disease Control. Mr. Strongo states that “the statement about the death toll reaching 500,000 is staggering, and it is our responsibility to be tested and to follow the rules of the CDC. We must keep testing, wearing masks and following the rules of social distancing, as directed by the CDC. We can defeat this virus. We must not take it lightly. It has killed thousands.”
The market is growing because of the outbreak of the coronavirus (SARS CoV-2) pandemic, which has increased the demand for rapid testing across the world. As the number of people suffering from the viral infection increases, the demand for rapid testing, which allows detecting the virus quickly, is growing. The adoption of a population-wide testing approach, which includes household, individual testing, is one of the trends influencing the demand for Covid-19 diagnostics kits. The shift from symptomatic testing to mass testing in developed countries is another major factor affecting the market.
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.
As a third surge of the coronavirus threatens much of the United States, public health experts across the country say there still aren’t enough tests available to keep the virus under control.
About 30 million Covid-19 tests are given every month, according to estimates from The Atlantic magazine’s Covid Tracking Project. But studies have found that the U.S. would need millions more — 193 million a month, according to one report — to be effective.
The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test.
Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, GWHP offers a CE Mark for its high quality; rapid antibody test for COVID-19 and a EUA filing with the FDA is pending approval. In the interim, the US Navy in California has been using the test during 2Q20 and the Company has the capacity to deliver hundreds of thousands of tests, ramping up to 1 million per day. Currently, the Company offers 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the CLIA WAVED FDA.
https://www.otcmarkets.com/stock/GWHP/news/story?e&id=1827227